The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Tryptophan degradation and immune activation in Alzheimer's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Oxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
Aging, energy, and oxidative stress in neurodegenerative diseases
Beal, M. F. (1995) · Annals of Neurology · doi:10.1002/ana.410380304 · Cited by 1,440
Brain Serotonin Content: Physiological Regulation by Plasma Neutral Amino Acids
Fernstrom, J. D., & Wurtman, R. J. (1972) · Science · doi:10.1126/science.178.4059.414 · Cited by 1,160
HEYES, M. P., SAITO, K., CROWLEY, J. S., DAVIS, L. E., DEMITRACK, M. A., DER, M., DILLING, L. A., ELIA, J., KRUESI, M. J. P., LACKNER, A., et al. (1992) · Brain · doi:10.1093/brain/115.5.1249 · Cited by 680
Kaltschmidt, B., Uherek, M., Volk, B., Baeuerle, P. A., & Kaltschmidt, C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2642 · Cited by 616
The Soluble Interleukin-2 Receptor: Biology, Function, and Clinical Application
Rubin, L. A., & Nelson, D. L. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-8-619 · Cited by 602
Buxbaum, J. D., Oishi, M., Chen, H. I., Pinkas-Kramarski, R., Jaffe, E. A., Gandy, S. E., & Greengard, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10075 · Cited by 559
Meltzer, M. D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00194-2 · Cited by 517
Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices
Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., Yolk, B., & Berger, M. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80737-n · Cited by 483
Cited by
A Meta-Analysis of Cytokines in Alzheimer's Disease
Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.012 · Cited by 1,108
Tryptophan metabolism in health and disease
Xue, C., Li, G., Zheng, Q., Gu, X., Shi, Q., Su, Y., Chu, Q., Yuan, X., Bao, Z., Lu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.004 · Cited by 961
Endogenous kynurenines as targets for drug discovery and development
Stone, T. W., & Darlington, L. G. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd870 · Cited by 768
Tryptophan and the immune response
Moffett, J. R., & Namboodiri, M. A. (2003) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.2003.t01-1-01177.x · Cited by 760
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Kynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 628
Sochocka, M., Donskow-Łysoniewska, K., Diniz, B. S., Kurpas, D., Brzozowska, E., & Leszek, J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1188-4 · Cited by 584
Monitoring tryptophan metabolism in chronic immune activation
Schröcksnadel, K., Wirleitner, B., Winkler, C., & Fuchs, D. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.013 · Cited by 551
Self-citationMicrobiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis
Westfall, S., Lomis, N., Kahouli, I., Dia, S. Y., Singh, S. P., & Prakash, S. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2550-9 · Cited by 541
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
An expanding range of targets for kynurenine metabolites of tryptophan
Stone, T. W., Stoy, N., & Darlington, L. G. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.09.006 · Cited by 344
How important is tryptophan in human health?
Kałużna-Czaplińska, J., Gątarek, P., Chirumbolo, S., Chartrand, M. S., & Bjørklund, G. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1357534 · Cited by 333
Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus
Guillemin, G. J., Brew, B. J., Noonan, C. E., Takikawa, O., & Cullen, K. M. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00655.x · Cited by 330
Kynurenine and its metabolites in Alzheimer's disease patients
Gulaj, E., Pawlak, K., Bien, B., & Pawlak, D. (2010) · Advances in Medical Sciences · doi:10.2478/v10039-010-0023-6 · Cited by 285
Probiotic Supplementation in Patients with Alzheimer’s Dementia - An Explorative Intervention Study
Leblhuber, F., Steiner, K., Schuetz, B., Fuchs, D., & Gostner, J. M. (2018) · Current Alzheimer Research · doi:10.2174/1389200219666180813144834 · Cited by 269
Self-citationIDO and Kynurenine Metabolites in Peripheral and CNS Disorders
Huang, Y.-S., Ogbechi, J., Clanchy, F. I., Williams, R. O., & Stone, T. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00388 · Cited by 187
Time to test antibacterial therapy in Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Watling, M., & Imbimbo, B. P. (2019) · Brain · doi:10.1093/brain/awz244 · Cited by 161
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142
The kynurenine pathway and inflammation in amyotrophic lateral sclerosis
Chen, Y., Stankovic, R., Cullen, K. M., Meininger, V., Garner, B., Coggan, S., Grant, R., Brew, B. J., & Guillemin, G. J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9129-7 · Cited by 141
“There is enhanced IDO activity and accelerated TRP degradation in several neurodegenerative diseases ( Widner et al. 2000, 2002 ).”
BackgroundStrasser, B., Becker, K., Fuchs, D., & Gostner, J. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.030 · Cited by 97
Self-citationKynurenine pathway in psychosis: evidence of increased tryptophan degradation
Barry, S., Clarke, G., Scully, P., & Dinan, T. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089583 · Cited by 96
Sharma, A., Kazim, S. F., Larson, C. S., Ramakrishnan, A., Gray, J. D., McEwen, B. S., Rosenberg, P. A., Shen, L., & Pereira, A. C. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903566116 · Cited by 92
Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients
González-Sánchez, M., Jiménez, J., Narváez, A., Antequera, D., Llamas-Velasco, S., Martín, A. H.-S., Molina Arjona, J. A., López de Munain, A., Lleó Bisa, A., Marco, M.-P., et al. (2020) · Biomolecules · doi:10.3390/biom10040571 · Cited by 84
Knock-on effect of periodontitis to the pathogenesis of Alzheimer’s disease?
Leblhuber, F., Huemer, J., Steiner, K., Gostner, J. M., & Fuchs, D. (2020) · Wiener klinische Wochenschrift · doi:10.1007/s00508-020-01638-5 · Cited by 77
Self-citation
Metadata
- Authors
- Widner, B., Leblhuber, F., Walli, J., Tilz, G. P., Demel, U., & Fuchs, D.
- Venue
- Journal of Neural Transmission
- Published
- 2000-03-15
- Volume
- 107
- Issue
- 3
- Pages
- 343-353
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2055523179
- Cited by
- 286
- References
- 40
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.